Study: Biomarkers help predict MCI progression to Alzheimer's

03/21/2013 | MedPage Today (free registration)

Cerebrospinal fluid biomarkers, such as amyloid B-42, T-tau and P-tau, could help pinpoint patients with mild cognitive impairment who are likely to develop Alzheimer's disease, according to findings presented at a neurology meeting. Patients with MCI who progressed to Alzheimer's in three years had lower baseline levels of amyloid B-42 and higher baseline T-tau and P-tau compared with patients with stable cognitive impairment or other forms of dementia. Assessment of the biomarkers yielded 89% sensitivity, 77% specificity, 73% positive predictive value and 91% negative predictive value, said the study, which used MRI and PET scans as part of the methodology.

View Full Article in:

MedPage Today (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Counsel, Regulatory (FDA)
CareFusion
San Diego , CA
Compliance Sr Mgr
Amgen
Thousand Oaks, CA
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Paralegal
Mylan Inc.
Washington, DC
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA